Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13
Viatris Analyst Ratings
Viatris Analyst Ratings
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11
Viatris Analyst Ratings
B of A Securities Downgrades Viatris to Underperform, Announces $9 Price Target
Viatris Analyst Ratings
Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS)
Barclays Downgrades Viatris to Underweight, Announces $11 Price Target
Barclays Downgrades Viatris to Equal-Weight, Lowers Price Target to $11
Barclays Downgrades Viatris to Equal-Weight, Announces $11 Price Target
Barclays Maintains Overweight on Viatris, Raises Price Target to $16
Barclays Adjusts Price Target on Viatris to $16 From $15, Keeps Overweight Rating
BMO Capital Downgrades Viatris to Market Perform, Lowers Price Target to $14
Barclays Adjusts Price Target on Viatris to $15 From $16, Maintains Overweight Rating
Jefferies Upgrades Viatris to Buy, Raises Price Target to $15
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $14
UBS Upgrades Viatris to Neutral From Sell, Adjusts Price Target to $12 From $9